Why the study?
Does the addition of a beta-blocker reduce bepridil-induced increases in QT dispersion and transmural dispersion of repolarization in patients with intractable paroxysmal atrial fibrillation?
Does the addition of a beta-blocker reduce bepridil-induced increases in QT dispersion and transmural dispersion of repolarization in patients with intractable paroxysmal atrial fibrillation?
The addition of a beta-blocker to bepridil therapy mitigates bepridil-induced increases in QT dispersion and transmural dispersion of repolarization, potentially reducing the risk of torsades de pointes.
May support beta-blocker co-use with bepridil to limit repolarization dispersion; hypothesis-generating for TdP risk reduction in paroxysmal AF.
Bepridil is effective for intractable cardiac arrhythmia, but in rare cases will induce torsades de pointes (TdP) associated with QT interval prolongation. Beta-blockers will effectively prevent TdP in some clinical settings, so the effect of beta-blocker on the change in QT interval, QT dispersion and transmural dispersion of repolarization (TDR) induced by bepridil was investigated in 10 patients (7 male, 3 female; 62+/-6 years old) with intractable paroxysmal atrial fibrillation. The QTc interval, QTc dispersion and TDR were measured before and after 1 month of administration of bepridil, and then a beta-blocker was added and the QTc interval, QTc dispersion and TDR re-measured 1 month later. Bepridil significantly prolonged the QTc interval (0.42+/-0.05 to 0.50+/-0.08; p<0.01), and increased both the QT dispersion (0.07+/-0.05 to 0.14+/-0.08; p<0.01) and TDR (0.10+/-0.04 to 0.16+/-0.05; p<0.01). The addition of a beta-blocker decreased the QTc interval (0.50+/-0.08 to 0.47+/-0.04; p=0.09) and significantly decreased both the QTc dispersion (0.14 +/-0.08 to 0.06+/-0.02; p<0.01) and TDR (0.16+/-0.05 to 0.11+/-0.04; p<0.001). Compared with the control, the combination therapy significantly prolonged the QTc interval, but did not increase either QTc dispersion or TDR, and so was effective in all patients with intractable AF. The findings suggest that beta-blocker reduces the increase in QT dispersion and TDR induced by bepridil, and combined therapy with bepridil and beta-blocker might thus be useful for intractable atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Yoshiga et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: